MCF Advisors’s GSK GSK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $26.8K | Sell |
484
-102
| -17% | -$5.53K | ﹤0.01% | 746 |
|
|
2025
Q4 | $28.8K | Buy |
586
+202
| +53% | +$9.42K | ﹤0.01% | 616 |
|
|
2025
Q3 | $16.6K | Hold |
384
| – | – | ﹤0.01% | 614 |
|
|
2025
Q2 | $14.7K | Hold |
384
| – | – | ﹤0.01% | 596 |
|
|
2025
Q1 | $14.9K | Hold |
384
| – | – | ﹤0.01% | 599 |
|
|
2024
Q4 | $13K | Hold |
384
| – | – | ﹤0.01% | 619 |
|
|
2024
Q3 | $15.7K | Hold |
384
| – | – | ﹤0.01% | 591 |
|
|
2024
Q2 | $14.8K | Hold |
384
| – | – | ﹤0.01% | 588 |
|
|
2024
Q1 | $16.5K | Hold |
384
| – | – | ﹤0.01% | 562 |
|
|
2023
Q4 | $14.2K | Hold |
384
| – | – | ﹤0.01% | 560 |
|
|
2023
Q3 | $13.9K | Hold |
384
| – | – | ﹤0.01% | 535 |
|
|
2023
Q2 | $13.7K | Hold |
384
| – | – | ﹤0.01% | 527 |
|
|
2023
Q1 | $13.7K | Hold |
384
| – | – | ﹤0.01% | 531 |
|
|
2022
Q4 | $13.5K | Hold |
384
| – | – | ﹤0.01% | 498 |
|
|
2022
Q3 | $11K | Hold |
384
| – | – | ﹤0.01% | 540 |
|
|
2022
Q2 | $21K | Hold |
384
| – | – | ﹤0.01% | 436 |
|
|
2022
Q1 | $21K | Buy |
+384
| New | +$20.9K | ﹤0.01% | 454 |
|
|
2021
Q4 | – | Sell |
-384
| Closed | -$18K | – | 304 |
|
|
2021
Q3 | $18K | Hold |
384
| – | – | ﹤0.01% | 427 |
|
|
2021
Q2 | $19K | Hold |
384
| – | – | ﹤0.01% | 388 |
|
|
2021
Q1 | $17K | Hold |
384
| – | – | ﹤0.01% | 384 |
|
|
2020
Q4 | $18K | Hold |
384
| – | – | ﹤0.01% | 347 |
|
|
2020
Q3 | $18K | Hold |
384
| – | – | ﹤0.01% | 328 |
|
|
2020
Q2 | $20K | Hold |
384
| – | – | ﹤0.01% | 307 |
|
|
2020
Q1 | $18K | Buy |
+384
| New | +$20.5K | ﹤0.01% | 314 |
|
|
2017
Q2 | – | Sell |
-987
| Closed | -$52K | – | 508 |
|
|
2017
Q1 | $52K | Buy |
+987
| New | +$50.1K | 0.01% | 226 |
|
|
2016
Q2 | – | Sell |
-219
| Closed | -$11K | – | 552 |
|
|
2016
Q1 | $11K | Buy |
219
+3
| +1% | +$149 | ﹤0.01% | 314 |
|
|
2015
Q4 | $11K | Buy |
216
+3
| +1% | +$153 | ﹤0.01% | 323 |
|
|
2015
Q3 | $10K | Buy |
213
+3
| +1% | +$156 | ﹤0.01% | 316 |
|
|
2015
Q2 | $11K | Buy |
210
+3
| +1% | +$169 | ﹤0.01% | 319 |
|
|
2015
Q1 | $12K | Buy |
207
+3
| +1% | +$172 | ﹤0.01% | 305 |
|
|
2014
Q4 | $11K | Buy |
204
+3
| +1% | +$168 | ﹤0.01% | 300 |
|
|
2014
Q3 | $13K | Buy |
201
+3
| +2% | +$184 | ﹤0.01% | 291 |
|
|
2014
Q2 | $13K | Sell |
198
-736
| -79% | -$49.8K | ﹤0.01% | 290 |
|
|
2014
Q1 | $62K | Buy |
934
+740
| +381% | +$50K | 0.02% | 168 |
|
|
2013
Q4 | $13K | Hold |
194
| – | – | ﹤0.01% | 263 |
|
|
2013
Q3 | $13K | Buy |
+194
| New | +$12.5K | 0.01% | 263 |
|
Other funds holding GSK
JEST
MCF Advisors's GSK Position: Q1 2026 in Review
MCF Advisors reduced its GSK (GSK) stake by 17% in Q1 2026, selling an estimated $5.53K and leaving 484 shares worth $26.8K. The position accounts for ﹤0.01% of the portfolio, ranked #746.
MCF Advisors first reported a position in GSK in Q3 2013 and has held it in 36 quarters since. The position peaked at $62K in Q1 2014. 1,031 funds tracked by Wall St. Rank hold GSK as of Q1 2026.
- MCF Advisors held 484 shares of GSK worth $26.8K as of Q1 2026.
- MCF Advisors sold 102 GSK shares in Q1 2026, an estimated $5.53K.
- GSK made up ﹤0.01% of MCF Advisors's portfolio in Q1 2026, its #746 holding.
- MCF Advisors first reported a position in GSK in Q3 2013 and has held it in 36 quarters since.
- MCF Advisors's GSK position peaked at $62K in Q1 2014.
- 1,031 funds tracked by Wall St. Rank held GSK as of Q1 2026.
Based on MCF Advisors's 13F filing for Q1 2026, filed 11 May 2026.